Natural antibodies: Protecting role of IgM in glioblastoma and brain tumours

Shubham Semwal¹, Rabah Boukherroub², Savvas N. Savvides³, Julie Bouckaert¹,*

¹Unité de Glycobiologie Structurale et Fonctionnelle, UMR 8576 from the CNRS and the University of Lille, 50 Avenue Halley, 59650 Villeneuve d'Ascq, France

²Univ. Lille, CNRS, Centrale Lille, Univ. Polytechnique Hauts-de-France, UMR 8520 - IEMN, F-59000 Lille, France

³Unit for Structural Biology, VIB – UGent Center for Inflammation Research, Department of Biochemistry and Microbiology, Ghent University, Technologiepark 71, 9052 Ghent, Belgium

Shubham Semwal <shubham.semwal@univ-lille.fr> 0000-0002-6941-5103
Rabah Boukherroub <rabah.boukherroub@univ-lille.fr> 0000-0002-9795-9888
Savvas N. Savvides <Savvas.Savvides@UGent.be> 0000-0003-3420-5947
Julie Bouckaert <Julie.Bouckaert@univ-lille.fr> 0000-0001-8112-1442

This is the author's accepted manuscript of the article published in Current Pharmaceutical Design. The final authenticated version is available online at: https://doi.org/10.2174/1381612827666210728103524
Cite this article as: Semwal Shubham, Boukherroub Rabah, Savvides N. Savvas and Bouckaert Julie*, Natural Antibodies: Protecting Role of IgM in Glioblastoma and Brain Tumours, Current Pharmaceutical Design 2021; 27(45) . https://dx.doi.org/10.2174/1381612827666210728103524
Abstract

Background: Glioblastoma is a grade IV astrocytoma with an average survival span for patients of 18 months after initial diagnosis and no standard treatment protocol. There is a need to look at novel approaches to target glioblastoma.

Objectives: This review intends to capture the role of immunoglobulin-M in cancer, more specifically in glioblastoma multiforme (GBM), and to compile the latest developments and immunological pathways relevant to glioblastoma

Methods: Information on glioblastoma, cancer microenvironment, cancer therapeutics and how to improve the scenario was obtained from scientific literature databases such as Pubmed, Medline, Google Scholar, Science Direct, Springer, Wiley online library and some data was harvested from regulatory and compliance databases such as clinicaltrials.gov, FDA database, WHO Globocan.

Results and conclusions: Currently, only a limited number of therapies are approved for GBM, and no standard of care is in place in case of disease relapse, necessitating a possible broader perspective in looking at the disease and its underlying mechanisms.

Keywords: IgM, Glioblastoma, Natural Antibodies, Immunotherapy, Microglia, ALK.
1. Introduction

The World Health Organization (WHO) defines cancer as a large group of diseases leading to uncontrollable and abnormal cell growth, spreading across the whole body or neighbouring tissues. According to the GLOBOCAN 2020, an online database from WHO, the global cancer burden lies around 19.3 million people with a mortality index of over 10 million deaths [1] (Fig. 1).

![Figure 1: Estimated number of new cases of different types of cancer in 2020 all across the world [1].](image)

On average, every fifth person develops cancer during their lifetime, with men having poorer survival odds [1]. Although not one of the leading cancers in terms of incidence or prevalence, brain cancer is currently ranked fourth in terms of the number of years of life lost. It is estimated that 308,102 people were diagnosed with brain cancer in the year 2020, out of which 251,329 succumbed to the tumour. These numbers put the current rate of fatalities at 81.5%, which is expected to reach 85.15% in the next 20 years with a 25.9% increase in the incidence[1] (Fig. 2).
Among brain cancer patients, about 27% suffer from glioma, a tumour consisting mainly of malignant glial cells. As per WHO classification, gliomas are classified and graded from type I to IV consisting of astrocytoma (I-IV), oligodendroglioma (grade II-III), mixed oligoastrocytoma (grade I–III), and ependymal tumours (grade I-II) [2]. Glioblastoma, also sometimes referred to as glioblastoma multiforme (GBM), is a special type of grade IV glioma defined by its anaplastic cellular nature with pleomorphic astrocytic cells with marked nuclear atypia and high mitotic rates. Primary glioblastoma starts straight from stage IV without showing any prior changes, whereas secondary glioblastoma is formed when a lower grade astrocytoma reaches grade IV [2, 3]. Nevertheless, except for a few genotypical changes, the overall expression of surface markers in primary and secondary glioblastoma are the same [3]. Therefore, genotyping glioblastoma is necessary to facilitate the appropriate choice of therapeutic approaches, which may lead to better survival rates [2-5].

1.1 Current therapies for glioblastoma

The primary step in standard health care for glioblastoma, like most of the other brain tumours, is dependent upon maximal resection of the tumour by surgery. Indeed, over the years, many studies have established that a higher subtotal and gross total resection is necessary for better survival chances [6, 7]. Apart from a better survival ratio, resection also serves some key factors such as reduction in tumour volume (lower chemotherapy needed), tumour genotyping (to identify the correct approach), and accurate histological diagnosis (type of brain cancer). To improve the surgical resection of GBM, 5-ALA (5-aminolevulinic acid, brand name Gliolan) was approved by FDA in 2017 [8]. 5-ALA is part of the mammalian heme biosynthetic pathway that cells metabolise and transform through a series of reactions in the mitochondria into protoporphyrin IX, a fluorescent metabolite [9]. Fluorescence-guided tumour resection surgery has gained much popularity because the administration of 5-ALA a couple of hours before anaesthesia
allows the intraoperative visualisation of malignant glioma cells [8, 10]. Although surgical resection is essential, it is commonly not the only method of care. It is usually accompanied by radiotherapy and chemotherapy. Radiotherapy has been used for a long time to reduce tumour size and improve control. The general dose of radiation given is a maximum of 60 Gy at a dose of 2 Gy – five days a week for six weeks accompanied with temozolomide treatment (Table 1). Temozolomide is the most widely used chemotherapy drug, usually given at 75 mg/m²[11, 12]. Due to recent advancements in treating GBM, the FDA approved Tumour Treating Field (TTF) back in 2011 as an adjuvant therapy alongside the standard of care therapeutics[13]. TTF is given by a device known as Optune®, which generates a low intensity, intermediate frequency (200 kHz) at 1-2 V/cm² of the patient’s scalp to induce anti-tumour effect via anti-microtubule action[12]. TTF has proven remarkable success in GBM treatment with only a minor side effect of making the patient suffer from mild to moderate dermatitis due to the recommended long-time duration (18h/day) [14]. On the contrary side of the spectrum, the EF-14 trial demonstrated no difference in health-related quality of life with the use of TTF apart from increased itchy skin[15]. These two separate sides make use of TTF quite controversial despite its FDA approval about a decade ago.

Table 1: List of FDA approved drugs for brain tumours.

<table>
<thead>
<tr>
<th>Therapeutic agent</th>
<th>Mechanism</th>
<th>Manufacturer</th>
<th>Approved for</th>
<th>Date of Approval</th>
<th>Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Afinitor Disperz</strong></td>
<td>mTOR inhibitors</td>
<td><strong>Zortress</strong></td>
<td>same as Everolimus</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Avastin</strong></td>
<td>Humanised monoclonal antibodies (mAb) against VEGF</td>
<td><strong>Genetech-Roche</strong></td>
<td>Cervical Cancer&lt;br&gt;Colorectal Cancer&lt;br&gt;Glioblastoma&lt;br&gt;Hepatocellular carcinoma&lt;br&gt;Nonsquamous non-small cell lung cancer&lt;br&gt;Ovarian epithelial, fallopian tube, or primary peritoneal cancer&lt;br&gt;Renal cell carcinoma</td>
<td>(June 2006) &lt;br&gt;(May 2009) &lt;br&gt;(2006) &lt;br&gt;(2018) &lt;br&gt;(2007)</td>
<td>[20, 21]</td>
</tr>
<tr>
<td><strong>BiCNU</strong></td>
<td>alkylating agent</td>
<td><strong>Emcure Pharmaceuticals</strong></td>
<td>Brain tumours&lt;br&gt;Hodgkin Lymphoma&lt;br&gt;Non-Hodgkin lymphoma</td>
<td>(July 1977)</td>
<td>[22]</td>
</tr>
</tbody>
</table>
Glioblastoma is known for its high relapse rate, and yet there is no standard of care procedure acceptable for relapsing patients as only a few of them can take secondary treatment. Due to the resistance of GBM cells to the treatment as well as the highly invasive nature of these cells, a very poor survival rate of 5 years in only about 5% of cases can be achieved. This has prompted efforts to better understand the tumour microenvironment as well as consideration of new approaches to treat GBM, such as immunotherapy.

Immunotherapy is rapidly becoming a pillar of anti-cancer therapy by harnessing the power of the host's immune system by inducing, enhancing, or suppressing immune responses to reject cancer cells. Immunotherapeutic approaches can be classified as active immunotherapy aimed at promoting a Th1 immune response through tumour vaccines, nonspecific immune stimulants, cellular vaccines, and as passive immunotherapy to induce an anti-tumour effect by transferring effector immune cells into patients. The first antigen-specific vaccine for castration-resistant prostate cancer, sipuleucel-T, was approved by the FDA in 2010[27]. A year later, the first checkpoint inhibitor for advanced melanoma, ipilimumab, was approved[27].

Tumour vaccines are made against tumour-specific antigens (TSA) that are primarily present only on tumour cells. The TSAs that arise from mutations of genes in the cancer cells are good candidates as suitable vaccine agents, given that such variants are absent in normal cells, thus making them safe to use. In theory, a TSA vaccine should not elicit any response against normal cells but would be expected to be effective against tumour cells. Epidermal Growth Factor Receptor variant III, commonly referred to as EFGRvIII, is a mutated version of EFGR lacking exon 2-7 (deletion), which renders it a unique amino acid sequence. This mutation renders cancer cells carrying this mutation with a truncated protein carrying an altered extracellular domain epitope[28]. This led to the development of Rindopepimut, a 13-amino acid EGFRvIII peptide vaccine conjugated with an adjuvant whose Phase-III clinical trials were recently completed successfully in 2017[29, 30]. Although Rindopepimut demonstrated great potential during its phase II clinical trial, resulting in increased overall survival correlated with the magnitude of induced tumour immunity[27, 31], it failed to show any drastic improvement in the patient's survival with newly diagnosed glioblastoma[29].

Another promising target for tumour vaccine development would be Anaplastic Lymphoma Kinase (ALK). The full-length ALK of ~220 kDa, including post-translational modifications like N-glycosylation, belongs to the receptor tyrosine kinase (RTK) [32]. Its intracellular C-terminal kinase domain is connected to several extracellular domains via a single transmembrane helix receptor [33]. ALK has been linked to cell development and differentiation, and its quantity starts decreasing as the gestation period increases, leaving ALK only in a few tissues, including the brain, testis, small
intestine, etc. Point mutations were found in ALK from different tumours, including neuroblastoma and glioblastoma [34]. In 2011, the FDA approved crizotinib as the first RTK inhibitor vaccine for non-small-cell lung cancer (NSCLC), but this drug exhibited serious side effects and a decrease in pharmacokinetic delivery due to its limited ability to cross the brain-blood barrier. This led to the development and repurposing of second-generation drugs like ceritinib, brigatinib and alectinib [35]. The major problem with ALK inhibitors is similar to other cancer vaccines, as cancer patients tend to develop resistance after treatment, making it problematic for cancer treatment in relapsing cases. The third generation of ALK inhibitors, lorlatinib and brigatinib, have been proposed to re-sensitise tumour cells to second-generation ALK inhibitors. Lorlatinib was approved by FDA in 2015 for NSCLCs and in 2018 for 2nd and 3rd line treatment of metastatic NSCLC. However, clinical trials are still ongoing for brigatinib, while some initial success was reported with lorlatinib [36-38]. The two examples mentioned above of rindopepimut and ALK inhibitors suggest that different approaches need to be developed to treat glioblastoma. Targeted immunotherapy in GBM is still in its infancy and matures at a slower but steady rate [39].

2. Cancer Immunology

The immune system has evolved to recognise invading pathogens. Understanding how it recognises and mounts a coordinated immune response to naturally occurring alterations of self-antigens during mutagenesis is ongoing. Most cells undergo transcriptional and translational mutations approximately 1,000–10,000 times per day, and even more frequently if a mutation successfully causes the cell to escape intrinsic repair mechanisms. The latter entails cases whereby an intact immune system can suppress this escape, known as extrinsic tumour suppressor mechanisms [40, 41]. Therefore, after an abnormal cell escapes intrinsic tumour suppressor mechanisms, it is imperative that it has a second line of defence that rapidly recognises these abnormal cells. In a healthy individual, the adaptive immune system consisting of B-cells, T-cells, dendritic cells, macrophages, and many more constantly roam across the human body and look out for the mutated and thus potential cancer cells to destroy them.

2.1 Immune surveillance in cancer

Immune surveillance is a natural process, which involves special types of WBCs called Natural Killer (NK) cells and T-cells to recognise the antigen provided by the cells using their MHC-I receptors. Under normal conditions, cells express self-proteins which are recognised by immune cells, thereby maintaining the cells healthy. When there is an anomaly such as a mutation in DNA during replication or damage to the cell due to radiation exposure or other causes, the cells start displaying specific molecules on the MHC-I as well as on receptors present on their surface, flagging them as stress signals. This makes them recognisable by T-cells, leading to the removal of the affected cells by apoptosis or phagocytosis. The NK cells have specialised receptors like NKG2D, a C-type lectin-like receptor that binds to stress signals and releases perforins and granzymes alongside cytotoxic T-cells that are activated by dendritic cells (DC) [42-44]. These molecules initiate a signalling cascade inside the tumour cells, causing apoptosis, assigning a major role to T-cells and NK cells in the process. As tumours evolve, they become heterogeneous by undergoing genetic changes that affect their surface receptors. Due to these changes, certain cells acquire the ability to evade the immune responses as they reduce MHC-I receptors on the cell and sometimes express certain immunosuppressive molecules like PDL1 (Protein-Death Ligand) that bind and
consequently inactivate the PD1 receptor on cytotoxic T-cells [45-47]. This process is known as immune editing, which consists of elimination, equilibrium, and escape. When tumour cells reach the escape phase, they are generally immune-edited to such an extent that they show high amounts of inhibitory checkpoint receptors, like PDL-1, that in turn shut down all the T-cells helping the cancer cells to evade the hosts' defence system [48]. Certain modern immunotherapies focus on dealing with tumours by either shutting down the immune checkpoints on specific T-cells or by making T-cells that can specifically target antigens on immune-edited tumours [49].

2.2 Tumour microenvironment of GBM and immune evasion mechanisms

In GBM, the tumour microenvironment is provided with immunosuppressive molecules that facilitate evasion of the natural immune response (Table 2). Cytokines such as Interleukin (IL)-1, IL-6, IL-10, prostaglandin E2 (PGE2), basic fibroblast growth factor (bFGF), and transforming growth factor (TGF-β) are produced in the GBM tumour microenvironment to promote tumorigenesis and suppress the immune response against tumours [49-51]. The GBM microenvironment also uses CD70, a ligand for CD27 and a member of the TNF receptor family of proteins, that elicits T-cell apoptosis by different mechanisms. Gangliosides and CD70 have been known to increase the tendency of T-cells to undergo apoptosis significantly. It is partially dependent on the receptor-dependent pathway as it is hypothesised that overexpression of CD70 on tumour cells triggers T-cell apoptosis; gangliosides are also related to immunosuppression, and T-cell apoptosis as T-cell apoptosis was found to decrease when ganglioside and CD70 functions were blocked [52-54]. Alongside CD27, programmed cell death protein-1 (PDL-1) ligand and FasL are also expressed on the surface of glial cells, which, as described earlier, can cause T-cell apoptosis [55]. The GBM microenvironment deals with angiogenesis and Treg (Regulatory T-cell) activation to further enhance tumour growth. As tumour cells grow rapidly, a hypoxic condition is created around the cells, enabling the GBM microenvironment to activate the Signal Transducer and Activator of Transcription 3 (STAT3), an immunosuppressive pathway and potent regulator of anti-inflammatory responses. STAT3 triggers the synthesis of hypoxia-inducible factor-1 (HIF-1), that subsequently induces activation of Tregs and production of vascular endothelial growth factor (VEGF) and promotes GBM cancer stem cells. Additionally, hypoxic conditions in the CNS trigger the transformation of macrophages into Tumour-Associated Macrophages (TAM), leading to a feed-forward mechanism of tumour-mediated immunosuppression [53, 54, 56, 57]. These types of TAM that support tumour growth are termed M2 cells, while the term 'M1' is used to annotate anti-tumour macrophages that are activated by the classical pathway involving interferon-γ [58].

Tumour cells have several mechanisms in their arsenal to evade the host's natural defence against tumour cells. In GBM, there are several mechanisms that prevent the clearance of defective tumour cells from the body. The tumour microenvironment plays a major role in providing the evasion mechanism as described earlier, but there are few other factors that aid the tumour cells. One such mechanism is modulating antigen presentation. GBM cells also stimulate the secretion of anti-inflammatory IL-10 and inhibit the production of TNF-α by microglia, further promoting suppression of the immune response (Table 2) [57]. Under certain conditions, central nervous system (CNS) antigens were detected in the perivascular space, indicating that these antigens can interact with immune cells like T-cells and DCs in cervical lymph nodes, thus providing a site for tumour antigen presentation [53, 59].
<table>
<thead>
<tr>
<th>No.</th>
<th>Component</th>
<th>Source of Origin</th>
<th>Effect on GBM</th>
<th>Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>IL-1ß</td>
<td>GBM microglia</td>
<td>↑ERK/MAPK activity; ↑VGEF; ↑JNK &amp; sphingosine kinase activity; ↑p38 MAPK activity; ↑drug resistance; ↑stemness factor gene; ↑IL-6 production.</td>
<td>[51, 60, 61]</td>
</tr>
<tr>
<td>2</td>
<td>IL-6</td>
<td>GBM microglia and plasma of GBM patient</td>
<td>IL-6 mouse fails to develop GBM; ↑JAK/STAT3 activation; ↑tumour heterogeneity; ↑stemness; ↑migration and evasiveness; ↑heterogeneity</td>
<td>[61]</td>
</tr>
<tr>
<td>3</td>
<td>IL-8</td>
<td>GBM microglia</td>
<td>↑proliferation and evasiveness; ↑angiogenesis; ↑tumour growth in autocrine manner</td>
<td>[61]</td>
</tr>
<tr>
<td>4</td>
<td>IL-10</td>
<td>TAM</td>
<td>↑immune suppression; ↑tumour growth; ↑Tregs; ↓MHC-II on monocytes; anergy in infiltrating T-cells; ↓TNF α &amp; IFN-γ; Polarizes TAM towards M2 phenotype</td>
<td>[60, 62, 63]</td>
</tr>
<tr>
<td>5</td>
<td>TGF-ß</td>
<td>TAM and GFC (TGF-ß2)</td>
<td>↑immune suppression, ↑tumorigenesis, blocks NK cells activity, ↓T-cells, ↑Tregs, ↓IL-2, ↓NKG2D on CD8+ T-cells, ↑CD133+; Polarises TAM towards M2 phenotype</td>
<td>[64-66]</td>
</tr>
<tr>
<td>6</td>
<td>CSF-1</td>
<td>GBM microglia</td>
<td>Polarises TAMs toward M2 phenotype; ↑TAM infiltration; blocking ↓ recurrence chances</td>
<td>[67, 68]</td>
</tr>
<tr>
<td>7</td>
<td>PGE2</td>
<td>Microglia/TAMs</td>
<td>Transforms DCs into regulatory phenotype</td>
<td>[69]</td>
</tr>
<tr>
<td>8</td>
<td>CD95</td>
<td>Microglia/TAMs</td>
<td>Stimulates AKT kinase; ↓GSK3ß; Induce Tc cell apoptosis.</td>
<td>[70]</td>
</tr>
<tr>
<td>10</td>
<td>CD59</td>
<td>GBM microglia</td>
<td>Enhances immunosuppression, inhibits the formation of MAC, prevents activation of the complement pathway</td>
<td>[5]</td>
</tr>
<tr>
<td>11</td>
<td>CD70</td>
<td>GBM cells</td>
<td>Mediates T-cell apoptosis through interaction with CD27</td>
<td>[52]</td>
</tr>
<tr>
<td>12</td>
<td>CD73 (adenosine)</td>
<td>GBM cells and Host cells</td>
<td>↑invasiveness (↑MMP9, ↑ECM degradation, ↓TIMP1); ↑VEGF; ↑MMP2; ↑α-dystroglycan; ↑AR2b AR signalling (↑Drug efflux, ↑Chemoresistance)</td>
<td>[71]</td>
</tr>
<tr>
<td>13</td>
<td>Factor H</td>
<td>GBM cells</td>
<td>↑cleavage of C3b to inactive iC3b; ↓deposition of C5b-9; ↑immunosuppression</td>
<td>[5]</td>
</tr>
</tbody>
</table>
14. CFHR5 (Complement Factor H related protein 5)  GBM cells  ↓ complement-mediated cell lysis; ↓ decay acceleration of C3 convertase; homologous to FH; ↑ immunosuppression. [5]

15. C1-IA (C1-inactivator)  GBM cells  ↓ complement system activation by binding to C1s and C1r; ↑ immunosuppression [72]

16. CCL22 and CCL2  GBM cells  Attracts Tregs by binding to CCR4 [73]

17. PDL-1  Microglia cells, TAM and GBM cells  Suppress Tc cell functions and proliferation by binding to PD-1; Production of Bregs. [4, 52, 53]

18. CTLA-4 (CD157)  GBM cells  naïve T-cell and memory T-cell activation; ↓T\text{h} cell activation; augments MDSC. [74]

19. MIC-1  Microglia cells, TAM  Polarises TAM towards M2 phenotype [75]

20. S100B  GBM cells  ↓ pro-inflammatory cytokines by TAMs; ↓ STAT3 pathway [76]

21. EGF  Microglia cells, TAM  ↑ tumour evasion and migration; ↑ phosphorylation of AKT to ↑MMP9. [77, 78]

22. VEGF  Microglia cells, TAM  ↑ vascularisation around a tumour; ↓ the ability of TAM to infiltrate GBM; ↓ innate immune system. [79, 80]

23. cmvIL-10  Infected GBM cells  ↓ DC maturation and antigen presentation; Impairs mononuclear cell proliferation; ↓ cytokine production; ↑ TGF-β production, ↓ MHC expression; ↑PDL-1 on tumours. [81]

24. FasL/CD95L  Astrocytes  Induces T-cell apoptosis [70]

* In the table ↑ represents upregulation or promotes; ↓ represents downregulation and ↓ means inhibits or stop.

Immunosuppressive cytokines secreted by GBM cells do not have a high enough systemic concentration to justify the impairment of peripheral immune cell functions. Impairment in antigen presentation capabilities alongside compromised T-cell activation of the immune system has been observed even in peripheral lymphatic tissue, irrespective of the underlying cause of the vitiated cell-mediated immunity. This, in turn, exacerbates the challenges to immunotherapeutic efforts. Several studies have shown that most Tregs originate in the thymus region, suggesting that there is probably a chemotactic attraction that drives Tregs of thymic origin near the tumour microenvironment [59, 82]. This is further strengthened by studies that suggest a role for an unidentified secretory molecule in Treg chemoattraction as blocking of CCR4, the receptor for CCL22 and CCL2 failed to abrogate Treg infiltration into GBM tumour mass [83, 84].

On the other hand, TAMs have a high expression of both CD11b and CD45 compared to microglia, which only display a high expression of CD11b, making it challenging for researchers to distinguish between the two types of cells as there is yet no distinguishable biological marker [85]. Recent studies have also shown that Myeloid Derived Suppressor Cells (MDSCs), which constitute the majority of the immunosuppressive force alongside TAM and cytokines in the vicinity of the tumour [86].
2.3 Localisation based effect of B-cells in tumours

The role of B-cells in immunity against cancer has been dubious as originally it was proved by Gordon et al. in 1982 that B-cells are necessary for early tumour antigen recognition and anti-tumour activity[87]. In 1989, Chow and Bennet hypothesised that B-cell recognition is necessary for the early detection of cancer by immunity [88]. However, the tide changed when seminal work by Schultz et al. showed that a B-cell-deficient mouse (muMT mice) does not display increased tumourigenesis compared to wild-type (WT) mice [89]. Over the past two decades, there have been many reports depicting the absence of B-cells in immunotherapy and focusing on T-cells for cancer-based immunity and cancer vaccines. However, some studies indicated that B-cells indeed are important, leading to the notion that muMT mice might present an exception due to different pathways or specific experimental factors.

The GBM microenvironment is also responsible for the conversion of B-cells that infiltrate tumours to regulatory B-cells (Bregs), which act as tumour protection cells. Bregs are not as well defined as Tregs, but recent studies on glioblastoma revealed that B-cells with both tumour suppressing and tumour promoting functions were present in the patients. This has led researchers to hypothesise that B-cells might present dual function, depending on their localisation: pro-tumourigenic function in the tumour (Breg) vs anti-tumour function in the periphery [90]. This theory is further supported by the fact that intra-tumoural depletion of B-cells results in the improvement of animal survival but is almost similar to systemic depletion of B-cells, indicating that only B-cells that are invading the tumour cells are transforming into Bregs by expressing PDL-1 and CD155 on their surface [91].

In 2014, two different research works were published highlighting how glioma produces ADAM-10 and placental growth, which are then recognised by naïve B-cells, transforming them into Bregs, ultimately resulting in suppression of CD8+ T-cells [92, 93]. In the GBM microenvironment, there are tumour-derived exosomes which are extracellular vesicles with an endosomal origin. These micro-vesicles are believed to carry PDL-1 from MDSC to the surface of B-cells, making them partially responsible for the production of Bregs [4]. The mechanism of B-cell infiltration in glioblastoma is still unclear, but it is well established that an adaptive B-cell that invades as a naïve B-cell ends up as a Breg, quite similar to a cytotoxic T-cell [91].

3. Natural antibodies and their role in immunosurveillance and immunotherapy

Antibodies are specialised glycoproteins that are secreted by immune cells to recognise the antigens and identify the immunogenic antigen. Antibodies are further classified based on their functional and structural organisation into five different classes, namely IgM IgG, IgA, IgD and IgE. IgM is rather distinct from any other antibody class, because it is the first antibody to be secreted against an immunogenic antigen. Interestingly, IgG is the class-switched IgM endowed with the ability to generate long-term and efficacious immunogenic memory. However, based on antigen stimulation, antibodies can be divided into two distinct classes, namely natural antibodies (nAbs) and adaptive antibodies, the latter more commonly known as secretory antibodies (aAbs or sAbs) (Fig. 3).

Natural antibodies are defined as antibodies or immunoglobulins that are present in the immune system in the absence of antigen stimulation [43]. These antibodies are very different from the adaptive immune system in several ways. They are the main ones responsible for the regulation of B-cell response, suppression of allergic response, protection from cancer, and clearance of apoptotic debris and tumours [94] (Fig. 3). They have a broader and more generalised response to infection.
when compared to adaptive B-cells. Although broader, the response is rather immediate and omnipresent thanks to the germline nature, a simple and primitive structure characterised by the lack of non-templated nucleotides, little to no hypermutation and a restricted repertoire [95-97].

NAbs are generally produced by specialised B-cells having surface expression as follows CD5+, IgMhigh, CD19high, B220low, IgDlow, CD23+ and CD43− [98] (Fig. 3). This expression profile is exactly the inverse of the one seen on normal B-cells, also known as adaptive B-cells (Fig. 3). The production of CD5 on the surface of T-cells was thought to be its distinct feature until it was recently found that some B-cell receptors are linked to natural IgM production, rendering them a specific subclass. Due to the earlier origin of NAb-producing B-cells, they are termed as B1 cells and the ones secreting adaptive Igs are termed as B2 cells; based on the presence or absence of CD5 receptor, B1 cells are further subclassified into B1a (CD5+) and B1b (CD5−) [99-101] (Fig. 3). It is postulated that B1a cells are produced during foetal development and are thereby maintained by self-renewal after the age of 3-6 weeks (neonatal development) [102]. Some studies showed that the expression of Lin28b induces a regulatory network of transcriptional regulators that support the development of B1a cells [103]. In the same study, it was stated that the Arid3a transcription factor is a key target of Let-7, whose ectopic expression is sufficient to induce B1 development in adult pro-B-cells and whose silencing by knockdown blocks B1 development in foetal pro-B-cells [103]. In the 1970s, studies demonstrated that antibody-producing cells specific for phosphorylcholine encoded by the T15 idiotype, later found to be expressed nearly exclusively by B1a cells, did not appear in the spleen and bone marrow until about one week after birth and were absent from the foetal liver [104].
Natural IgM antibodies are germline-coded by specific germline families and not affinity matured via somatic mutations like adaptive natural antibodies. Brezinschek et al. demonstrated that the majority of monoclonal natural antibodies had germline-encoded VH and VL regions, and almost 80% of antibodies contained overexpressed DP47 and DP49 germline genes belonging to the VH3 family [105]. Similar to genetic restriction in the VH domain, it was reported that 90% of monoclonal nAb obtained from patients incorporated κ-light chains, giving them a 97.2% and 100% degree of identity when compared to the most homologous germline genes [105]. The high homology between germline genes and the VH and VL region of nAbs obtained from cancer patients and healthy individuals, together with the fact that these Abs have a lower incidence of silent mutations (R/S ratio), indicate very transparently that these Abs are germline-coded [106].

Atif et al. have shown that a healthy immune system is required for the recognition of neoantigen-expressing cells [107]. They further demonstrated that a diverse polyclonal IgM, but not IgG, repertoire is required for the rejection of neoantigen cells. In addition, they suggested that natural IgM includes specificities able to recognise neoantigen-expressing cells, and IgM is required to initiate the immune response against neoantigen-expressing cells, as all other cell types, APC subtypes and CD4 and CD8 lymphocytes, are present in IghelMD4 mice yet they failed to generate any response against the neoantigen-expressing cells [107].

Moreover, natural IgM is a key player in immune complex formation, and several ex vivo studies include natural IgM binding on tumours in immunohistochemistry sections and tumour lysates in Western blots. The common hypothesis proposed by various scientists is that cellular immune complex formation, initiated by natural IgMs, i.e., antigen-antibody complexes, is likely to play a critical role during the early recognition and elimination phase of precancerous cells [106-110]. Earlier studies also show that IgM has a very high affinity (10 nM) for TOSO/FAIM3, a regulator of Fas-induced apoptosis, thereby indicating a role of TOSO in immune surveillance through internalisation of IgM-bound immune complexes that contribute to B-cell activation [111]. Recent studies have also indicated that mice with nIgM-deficit genes produced more auto-antibodies (IgG and IgA) than mice with normal nIgM production [112, 113]. It is evident that one of the roles of natural IgM antibodies includes the targeting of altered self-antigens or neo-epitopes on dying cells for targeted removal, thereby maintaining tissue homeostasis [107, 114].

One such antigen recognised by natural IgMs to facilitate the removal of apoptotic or dying cells is phosphorylcholine, which is also present on the cell wall of many parasites and microbes [115, 116], providing the first line of defence against pathogens. Carbohydrates, phospholipids, lipopolysaccharides, low-density lipoproteins, single- and double-stranded DNA are other antigen specificities known to be recognised by natural IgM antibodies, thus making it a very effective force against the tumour cells [106, 114]. It has been demonstrated that one of the key features of a tumour cell is the presence of altered glycopeptides or carbohydrate antigens on its surface, which in a healthy person are recognised by the innate immune system (nIgM, NK cells,
dendritic cells), leading in turn to apoptosis of these cells [114, 117]. Recently, Becker et al. discussed the role of Mannitou IgM; a murine IgM raised against a 130-kDa glycoprotein obtained from the leech CNS, in reducing the tumourigenesis of GBM when glioblastoma cell lines were grown in the presence of IgM antibodies [117]. AHNAK, a giant 629-kDa molecule, was found out to be paucimannosylated and recognised as the major tumour suppressor protein identified in the presence of Mannitou IgM as it leads to a reduction in migration, invasion and proliferation of GBM. However, it is still unknown how IgM upregulated AHNAK production, even though this discovery has put IgM on the map as yet again a potent anti-tumour molecule [117].

4. Why IgM and not IgG?

Chemotherapy was introduced in the repertory of therapeutic interventions in the 1940s. Initially, chemotherapy relied on toxic chemicals (molecules) that could kill the cancer cells. The dawn of targeted therapy or modern chemotherapy arguably began shaping in the late 20th century. Over 60 mAb-based drugs are currently approved and distributed with worldwide revenue of $138 – $163 billion in 2019 and with a Compound Annual Growth Rate (CAGR) of 12.0% through 2022 [118, 119]. There is a great potential in the market for mAbs both regarding drug delivery and immunotherapy. The aforementioned claim is demonstrated by PAT-SM6, a GRP78-targeting monoclonal antibody that is used for the treatment of melanoma [120, 121] and IGM-2323 for the shrinkage of non-hodgkin lymphoma as it contains nine high-affinity binding domains for CD20 and one binding domain for CD3 [122]. IGM-2323 is able to eliminate CD20-positive lymphoma cells by engaging T-cells and lymphoma cells, leading to T-cell dependent cellular cytotoxicity. Additionally, IGM-2323 is also able to eliminate lymphoma cells by recruiting complement to the surface of lymphoma cells, leading to complement-dependent cytotoxicity. In a study conducted in 2014, it was reported that novel IgM-based Antibody-Drug Conjugates (ADC) could be used to selectively kill chronic lymphocytic leukaemia cells. IgM-based ADC binds to the Fcμ receptor, which leads to rapid internalisation and intracellular cytotoxic payload delivery, making IgM a more suitable drug carrier than IgG counterparts as they lack the above-mentioned activity [123]. Although there are many non-IgG based drugs available in the market and clinical trials, IgG predominates [124]. This can mainly be attributed to the fact that IgGs were the first mAb to be cloned. IgG generally exists as a monomer, with a molecular weight of around 150 kDa, making it a relatively small immunoglobulin. IgG can trigger multiple pathways by interacting with the FcγR, found on many immune cells to mediate functions like Antibody-Dependent Cellular Cytotoxicity (ADCC) and to some extent trigger Complement-Dependent Cytotoxicity (CDC) [125]. Due to this property, they can easily travel in the bloodstream and diffuse to the target tissue, rendering high potency as a therapeutic molecule. To date, IgM has been largely left out from the biopharmaceutical market or ignored as their structural characteristics were difficult to understand, had a lower affinity when compared to IgG, showed cross-reactivity and most importantly had a pentamer structure [126]. In the early 21st century and following the discovery of natural antibodies, the tide took a turn as carbohydrates were involved as a new class of antigen separate from peptide-based antigens evolved. carbohydrates or glycoepitopes are now believed to be the main epitopes recognised by the natural immune system on tumour cells and are termed as Tumour Associated Antigen (TAA) or Tumour
associated Carbohydrate Antigen (TACA) [127]. Many studies revealed that glyco-epitopes are very different from traditional peptide-based epitopes as they share a wide array of structural homologies, making them prone to cross-react extensively, and thereby suitable ligands for highly valent nIgMs [110, 114]. A major advantage of IgM comes from their multimeric nature: recent electron microscopy imaging showed that IgM is a mushroom / turtle-shaped molecule with a central dome constructed by the Fc region of each chain from which the antigen-binding fragments (Fab) arms radiate outwards, flexible enough to make a move freely [128]. This unique feature of IgM (both nIgM and sIgM) makes them a potent activator of the complement system as they can easily and strongly bind to C1q in a 1:1 or 1:2 ratio to trigger the ADCC pathway. nIgM along while being a potent complement system activator, can also detect neoantigens and react to self-antigens (carbohydrate residues on the surface of cells), giving them a natural ability to apoptosize tumour cells thanks to the features mentioned above in combination with a limited gene pool [107]. Certain studies also show that IgM can bind very tightly to the glycan antigens with affinities in the sub-nanomolar range, making them better binders to glycan epitopes when compared to IgGs [129, 130]. Furthermore, despite their colossal size, IgM are able to invade tumour cells successfully, making them good candidates as therapeutic or diagnostic molecules [106].

A recent study by Samsudin et al. suggested that even two IgM molecules can act differently based on antigen recognition [131]. Their predictive model showed that Pertuzumab IgM displayed the best binding results as it was able to utilise all of its antigen-binding sites to bind to multiple HER receptors, while Trastuzumab IgM failed to do so due to steric hindrance, lending it a lower effective rate compared to their IgG counterparts [131]. This is a reminder that despite the advantages of IgMs over IgG, a suitable understanding of antigen-antibody interaction as well as a suitable mode of delivery is required to achieve maximum efficiency. IgM effectiveness has been proven recently in targeting different types of cancers like melanoma, stomach carcinoma, breast cancer, lung cancer, and many more based on the effective recognition of glycan epitopes [106, 107, 110, 132].

Table 3: List of monoclonal IgM antibodies that have undergone clinical trials.

<table>
<thead>
<tr>
<th>Antibody</th>
<th>Antigen</th>
<th>Production cell</th>
<th>Disease targeted</th>
<th>Clinical trial</th>
<th>Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td>XMMEN-0E5</td>
<td>J5 Lipid A</td>
<td>Hybridoma with mouse myeloma</td>
<td>Sepsis</td>
<td>Phase 3</td>
<td>[133]</td>
</tr>
<tr>
<td>HA-1A</td>
<td>J5 Lipid A</td>
<td>Heteromyeloma with lymphoma spleen cells</td>
<td>Sepsis</td>
<td>Phase 1</td>
<td>[134]</td>
</tr>
<tr>
<td>MAB-T88</td>
<td>LPS</td>
<td>Hybridoma with mouse myeloma</td>
<td>Neutropenia</td>
<td>Phase 1</td>
<td>[135]</td>
</tr>
<tr>
<td>Fanolesomab-Tc99</td>
<td>CD15 (carbohydrate)</td>
<td>Hybridoma with mouse myeloma</td>
<td>Appendicitis diagnosis</td>
<td>Phase 3</td>
<td>[136]</td>
</tr>
<tr>
<td>PAT-SC1</td>
<td>CD55 (glycan isofrom)</td>
<td>Recombinant production Per.C6 cells</td>
<td>Gastric cancer</td>
<td>Phase 1</td>
<td>[137]</td>
</tr>
<tr>
<td>mAb216</td>
<td>CDIM (carbohydrate)</td>
<td>Heteromyeloma with lymphoma spleen cells</td>
<td>B-lineage ALL</td>
<td>Phase 1</td>
<td>[138]</td>
</tr>
<tr>
<td>PAT-SM6</td>
<td>GRP78 (O-linked glycan)</td>
<td>Recombinant production Per.C6 cells</td>
<td>Multiple myeloma</td>
<td>Phase 1</td>
<td>[121]</td>
</tr>
<tr>
<td>L612</td>
<td>Ganglioside GM3</td>
<td>EBV-transformed patient B cells</td>
<td>Melanoma</td>
<td>Phase 1</td>
<td>[139]</td>
</tr>
</tbody>
</table>
Table 3 illustrates IgM mAbs that have been approved for clinical trials for their use as therapeutic agents. It is important to note that these IgM antibodies were well tolerated in the patients. Their antigens comprise lipopolysaccharides (LPS) and its component core structure lipid A, gangliosides, proteolipids, and glycans (Table 3), which are generally poorly immunogenic because of their non-protein nature, which makes it difficult to target them by the commonly used IgGs [142]. However, their repeated or polymeric antigenic motifs embedded in cell membranes allows the pentameric or hexameric IgM to bind in a multivalent fashion. Due to their avidity and polyreactivity by presenting 10 or 12 paratopes simultaneously to their antigens, IgM antibodies mAbs display a striking advantage over their IgG counterparts.

Apart from the detection of epitopes proper to cancer cells, the immune response can be boosted for nIgM. Kaveri et al. summarise several ways to induce and boost nIgM levels, like by exogenous administration of IL-18, the use of synthetic peptides that mimic poorly immunogenic non-protein antigens, and idiotypic vaccination strategies that boost IgM and IgG levels against NeuGcGM3 gangliosides antigen [111]. IL-18 is a strongly pro-inflammatory cytokine that has the ability to regulate the production of nAbs by inducing the expansion of the innate-type marginal zone B-cells subset [143] and the B1b cells [144]. These techniques can be investigated further to look into their potential as anti-cancer immunotherapy to be given alongside standard chemotherapy.

<table>
<thead>
<tr>
<th>MORAb-028</th>
<th>Ganglioside GD2</th>
<th>Hybridoma with human/mouse myeloma</th>
<th>Melanoma</th>
<th>Phase 1/2a</th>
<th>[140]</th>
</tr>
</thead>
<tbody>
<tr>
<td>rHIgM22</td>
<td>CNS myelin proteolipid</td>
<td>Recombinant</td>
<td>Multiple sclerosis/neuronal degeneration diseases</td>
<td>Phase 1</td>
<td>[141]</td>
</tr>
</tbody>
</table>

Studies have demonstrated that nIgM, more specifically HlgM12, has the potential to protect and remyelinate neurons, giving them a protecting role in the brain [144, 145]. It also established that IgM could cross the Blood Brain Barrier (BBB) intrinsically as nIgM doses were administered via intraperitoneal or intravenous routes in the murine models. The proposed mechanism of action of HlgM12 indicates that it binds GD1a and GT1b, complex gangliosides present in the plasma membrane of neurons. Gangliosides have a ceramide tail that anchors them to the plasma membrane while the external glycan moieties protrude out to act as a receptor for different kinds of ligands. HlgM12 probably clusters ganglioside-rich membrane microdomains into larger complexes. Precisely, HlgM12 first binds to the neuronal membrane by colocalising with GM1 and cholesterol, thus segregating into the lipid-raft fraction and overriding myelin- and MAG-driven inhibition of neurite extension [145].

5. Targeting GBM across the Brain Blood Barrier
The major setback of detecting or treating GBM has always been its location, as it is most of the time protected by BBB, which acts like a filtering membrane keeping most of the toxins and serum albumins away from the brain. It is a major limiting factor for mAb-based drugs and immunotherapy as only 0.1% to 0.6% mAb is reported to enter the target site, thereby needing patients to take relatively very high doses of even the most potent mAbs (100 mg/kg of body weight) [124]. There are several approaches tried by scientists over five decades to overcome this barrier ranging from physical to
chemical disruption of BBB. Theoretically, the primary route of administration is to directly inject the therapeutic agent into the brain parenchyma or cerebrospinal fluid (CSF) (Fig. 4). This is predominantly used in experimental work and preclinical, but never in a clinical trial due to a higher risk of damage via the needle or of infection in the brain. Moreover, even if the drug is directly introduced into the brain/tumour site, it barely moves across the injection site due to the highly compact nature of brain tissues, making it a highly inefficient route of drug administration [146-148]. The effectiveness of the drug has been reported to reduce simultaneously when the drug is introduced via CSF due to the passage to the surrounding parenchymal tissue being diffusive in nature. This slow process is even more problematic when dealing with therapeutic molecules such as IgM or IgGs due to their sheer size and rapid removal via the glymphatic system [149-151].

During the 1980s, various methods such as osmotic (intracarotid mannitol) disruption were tried to temporarily remove or disrupt the BBB via endothelial shrinkage, resulting in the opening of tight junctions [152, 153] (Fig. 4). These methods were largely effective but never reached clinical trials as nontargeted disruption led to the entry of many unwanted and toxic serum proteins and inflammatory molecules that are generally filtered out due to the presence of BBB [154]. Similar is the case of targeted methods like the use of bradykinin and analogues, as they succeeded in preclinical trials but were never put forward for clinical trials probably due to a short active span to prevent inflow of toxic serum proteins [155, 156]. The most efficient method to disrupt the BBB and allow the influx of monoclonal therapeutic antibodies comes in the form of high-power focused ultrasound, but it suffers from a major disadvantage such as damage and distortion of neighbouring tissues [157-159].

(Fig. 4). In order to surpass this obstacle, microbubbles are introduced alongside with low-frequency ultrasound, resulting in microbubble cavitation and oscillation, leading to disruption of BBB in the local vicinity. This approach is one of the most promising methods to deliver IgM-based nanobodies, but the studies lack the long-term consequences and the degree of penetration that can be achieved based on this method as the efflux transport mechanism remains active [157, 160, 161] (Fig. 4). Moreover, the contraction and expansion of air bubbles create thermal energy, which, in turn, can physically damage cells, causing cell death [162].

While most of the above-mentioned methods highlight the disruption of BBB to increase the uptake of therapeutic molecules in the BBB, an alternative practice is to improve the uptake of the therapeutic or diagnostic molecules by modifying the agent itself. This is mainly achieved by making the carrier molecule more lipophilic and the drug more receptive in the brain, but at the cost of increased off-target effects, as a result of membrane permeability [163, 164] (Fig. 4).

Nanocarriers were introduced that were made from diverse structures such as liposomes, phospholipids, polymer-based particles, and many other molecules with the common goal to be loaded with the drug/therapeutic agent and to deliver it across the BBB into the brain. These special particles are termed as nanoparticles [165]. Once the nanoparticle reaches the brain, the change in chemical surroundings like pH or exclusive molecules present in the tumour microenvironment destabilises the nanocarrier, resulting in effective drug delivery [166] (Fig. 4). However, the main problem in using nanoparticles in the brain is that they tend to release a small amount of drug at nonspecific sites en-route to the target site and all across the brain, making them less efficient. In order to overcome this
problem, molecular tags like transferrin, EGFP-EGF1 fusion protein, metalloprotease-2 are used as they specifically bind to receptors present on GBM cells like TfR-1 bind transferrin, while tumour-expressed chloride channels bind cholera toxin [11, 78, 167]. These tag-infused nanoparticles hold significant promise for drug delivery but still do not answer the problem related to the transfer of large molecules like IgM or other therapeutic antibodies [168]. Apart from this, only a few of them are undergoing clinical trials for GBM, and none of them are close to being approved [169-171].

In order to deliver protein macromolecules like therapeutic antibodies, a process known as receptor-mediated transcytosis is used. It is a direct molecular tagging of the therapeutic molecule itself and is considered as the best possible solution as they are recognised by endothelial transporters [171, 172]. Alongside, many alternative approaches have been developed for effective transfer of therapeutic antibodies across BBB, such as making Fc domains of antibodies specific against the endothelial receptors so that they get accepted more easily, [173] or modifying an Abs with one Fab arm recognising an endothelial transporter while the other Fab arm is specific towards the targeted antigen[174, 175] (Fig. 4). Some studies also included linking an endothelial transporter domain onto the light and heavy chains [176]. In a recent study conducted by Galstyan et al., it was demonstrated that by conjugating already existing anti-CTLA-4 and anti-PD-1 IgG antibodies with a natural biopolymer scaffold-like polyβ-L-malic acid or 3-(2-pyridyldithio) propionate (PDP) significantly increased its absorption across BBB [176] (Fig. 4).

Nevertheless, despite substantial recent advances, it is still challenging to deliver precisely a relevant dose of therapeutic antibodies to the human brain, mainly due to the fact that BBB is such a selective and complex barrier that its disruption can cause more harm than good to the patient in the long-term. On the other hand, molecules like IgM, which are already in the nanomolar range, can be used to deliver the drug or in diagnostics by conjugating it with a fluorescent marker like 5-ALU for early diagnosis of GBM.
**CONCLUSION**

Upon surveyal of the literature, we can conclude that IgM antibodies hold the potential to be used as potent anti-cancer therapeutics in the coming years. It has already been proven that natural IgM antibodies have a protective role against cancer, especially glioblastoma. With the gradual improvement in drug delivery systems and a better understanding of the biochemical and immunological interactions, we should be able to better target GBM cancer cells across the BBB in the near future. There are currently many IgM-based drugs in the pipeline, but there is a need to understand the interactions of IgMs better, as explained by Samudin et al. [115], to gain a significant improvement in the survival span of the patients. Current knowledge on the treatment of GBM by targeted therapy is still limited; hence, further research on the role of IgM in GBM is warranted.

**AUTHORS’ CONTRIBUTION**

The authors contributed to data acquisition, analysis, and manuscript preparation. The first author designed the review and prepared the initial review. The co-authors provided their expertise and provided additional data and suggestions to improve the quality of the article. Finally, the corresponding author critically reviewed the article and made necessary amendments to prepare the article for publication.

**FUNDING**

The authors acknowledge financial support through the Programme for EARly-stage Researchers in Lille (PEARL), under the auspices of the European Union Horizon 2020 research and innovation programme, project "ATACA" with Marie Sklodowska-Curie agreement No. 847568. PEARL is coordinated by the Foundation I-SITE ULNE and implemented at the Centre National de la Recherche Scientific (CNRS).

**ACKNOWLEDGEMENTS**

The authors express their gratitude to the University of Lille for granting MOBLILEX mobility to Lille for Shubham Semwal. Furthermore, we are grateful to Dr. Vibha Gupta at the Jaypee Institute of Information Technology (JIIT) in Noida, India, for elaborate discussions on the topic.

**CONSENT FOR PUBLICATION**

Declared none.

**CONFLICT OF INTEREST**

The authors declare no conflict of interest, financial or otherwise.
REFERENCE

[1] WHO | IARC - International Agency for Research on Cancer 2020 [Available from: https://gco.iarc.fr/today_online-analysis-map?v=2020&mode=population&mode_populations=continents&population=900&population_group%5B%5D=0&ages_group%5B%5D=17&nb_items=10&group_cancer=1&include_nmssc=1&include_nmssc_other=1&projection=natural-earth&color_palette=default&map_scale=quantile&map_nb_colors=5&continent=0&show_ranking=0&rotate=%25202C0%255D.


[97] Tornberg UC, Holmberg D, B-1a, B-1b and B-2 B cells display unique VHJDH repertoire formed at different stages of ontogeny and under different selection pressures. EMBO J. 1995;14(8):1680-9.
[113] Boes M, Schmidt T, Linkemann K, Beaudette BC, Marshak-Rothstein A, Chen J. Accelerated development of IgG autoantibodies and autoimmune disease in...


[140] Safety Study of Human IgM (MORAb-028) to Treat Metastatic Melanoma. [Internet]. [cited 20 May 2021].


